Clinical Characteristics And Prognostic Analysis Of198Cases With Difffuse Large B Cell Lymphoma(DLBCL)

Purpose and Background:Diffuse large B-cell lymphoma(DLBCL) is the most common aggressive non-Hodgkin’s lymphoma,a number of studies have shown that its pathogenesis involves chromosome translocation,amplification,deletion and mutation and other aspects.In clinical pathology,the diseasehas a high degree of heterogeneity,mainly in the clinical features,immune phenotype,differences in treatment responseand prognosis are inconsistent.This article is intended toanalyze the relationship between diffuse large B-cell lymphoma general clinical features,laboratory tests,such as tumor cell origin and prognosis to guide therapy.Methods:198patients were collected in January2003toOctorber2013from Third Affiliated Hospital of Jilin University, confirmed diffuse large B-cell lymphoma by biopsy from pathology department.Main outcome following indicatorsof median overall survival (OS),the median progression-freesurvival (PFS) effects:age,lactate dehydrogenase (LDH),group B symptoms,clinical stage,international prognostic index (IPI),the primary site of tumor growth index (Ki-67),Bcl-2,CD5,the origin of tumor cell.Statistical analysis of relevant data, respectively, using SPSS21.0software, statisticalanalysis, application of Kaplan Meier method to calculatethe survival rate and survival function, the Log-Rank test is used to single factor analysis, multiple factors analysis using COX regression model, count data using X2test.(P <0.05) was statistically significant, P <0.05for significant statistical significance.Results:In this paper,198patients with DLBCL, men areslightly more than women. Less than or equal to60years old is accounted for62.12%(123cases). Group B symptoms isaccounted for34.85%(69cases). PS score of2points or79.30%(157cases). Clinical stage III-IV disease is accounted for56.57%(112cases). IPI prognosis grouping, low-risk group is44.95%(89cases),20.71%low risk group (41cases),22.22%in high-risk group (44cases),12.12%high-risk group (24cases). Primary in the junction is of72.22%(143cases), outside the junction lesions with primary in thegastrointestinal is tract most,9.96%(19cases).LDH is increased40.91%(81cases). β2microglobulin rise29.30%(5 8cases). Of198patients,198cases of tumor tissue is examined the Bcl-2protein, multiple with positie, is accounted for73.88%(99cases). There are84cases of tumor tissue examined CD5protein, multiple by negative, is accountedfor80.95%(68cases). A total of161cases of tumor tissue source judgment to tumor cells, and in a non-multiple GCB type, accounting for67.08%(108cases). With165casesexamined Ki-67, expression is given priority to with50%or higher, accounting for92.73%(153cases).In cases of patients with different cell sources in gender, age, diseasesymptoms, clinical stage, group B, PS score, IPI, LDH, β2microglobulin, CD5, Bcl-2, Ki-67, P values were greaterthan0.05, the prompt GCB and non-GCB in no difference in clinical features associated with performance. To investigate the relationship between clinical features and prognosis of DLBCL, has carried on the single factor and multiplefactors that affect the median surial analysis, results show that in the single factor analysis, sex, site, β2microglobulin level, the Bcl-2, Ki-67expression state had noeffect on animal survival;, group B symptoms, PS score and age, clini cal stage, LDH level, IPI, tumor cell source, whether CD5expression status, application of rituxan treatment affect the prognosis of patients, P values were0.0250,0.0198,0.0001,0.0001,0.0008,0.0110,0.0328,0.0087,0.0328. Multiple factors analysis showed that IPI, level of physical fitness score, β2microglobulin, tumor cell source, whether application of rituxan treatment is the independent prognostic factor in DLBCL, P values are:0.0260,0.0403,0.0262,0.0403,0.0262.Conclusion:1.Group DLBCL studies show that male incidenceis slightly higher than women, the non-elderly group rates ishigher than the elderly group, the majority of patients withknot come on inside and outside the junction with highestincidence of gastrointestinal disease. Although a few patientswith symptoms of group B, but a PS2or more points is themajority, the patients with more than half of III-IV isconsistent. Not to the half of the patients serum LDH and microbeta globulin increases. Non-GCB patients had a significantlyhigher incidence of GCB, Bcl-2positive expression rate ishigh, while negative CD5expression rate is high, the vastmajority of patients with Ki-67expression is more than50%. 2.Gender,age,disease parts,clinical stage,group B,IPI,ecog score,LDH,β2microglobulin,CD5,Bcl-2,Ki-67has nocorrelation with tumor cell sources.3.Age,group B symptoms,ecog score,IPI,clinical stage,LDH,cell source,CD5,rituximab is the factors affecting theprognosis of DLBCL.4.IPI,ecog score,β2microglobulin,cell source, rituximab is independent prognostic factor of DLBCL..